4D Molecular Therapeutics Inc FDMT
$15.83 $0.27 (1.68%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
FDMT Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, 4D Molecular Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
4D Molecular Therapeutics Inc. Stock Analysis FDMT
United States Health Care Small Cap 4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. The company is headquartered in Emeryville, California and currently employs 196 full-time employees. The company went IPO on 2020-12-11. The firm's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The firm is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The firm's non-core programs include 4D-175, 4D-725, and 4D-310.
4D Molecular Therapeutics Inc (FDMT) Chart
Financial Metrics & Statements of 4D Molecular Therapeutics Inc (FDMT)
FAQ's for 4D Molecular Therapeutics Inc (FDMT)
- As of August 2026, 4D Molecular Therapeutics Inc FDMT is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes 4D Molecular Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in 4D Molecular Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of 4D Molecular Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of 4D Molecular Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of 4D Molecular Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for 4D Molecular Therapeutics Inc (FDMT)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
